Source: Health Products Regulatory Authority (IE) Revision Year: 2003 Publisher: Smith & Nephew Pharmaceuticals Limited, P.O. Box 81, Hessle Road, Hull, HU3 2BN, England
Iodoflex consists of cadexomer iodine in a macrogol base applied to a polyester gauze carrier. In contact with wound exudate Iodoflex absorbs fluid, removes exudate, pus and debris from the wound surface. One gram of cadexomer iodine can absorb up to 6ml of fluid. Iodine is physically immobilised within the matrix of the dry cadexomer iodine and is slowly released in an active form during uptake of wound fluid. This mechanism of release provides antibacterial activity both at the wound surface and within the formed gel. There is no evidence of the development of bacterial resistance to iodine. The formed gel can easily be removed without damaging the fragile new epithelium underneath.
Systemically absorbed iodine from Iodoflex is rapidly and almost exclusively excreted into the urine. Cadexomer is biodegradable by amylases, normally present in wound fluid.
In preclinical studies, Iodoflex has been shown not to interfere with normal wound healing. Toxicity studies with daily skin applications of Iodoflex for 6 months in rabbits showed no evidence of local or systemic toxic effect. Iodoflex did not cause sensitisation in animals.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
